{"id":"enstilar-0-005-0-064-topical-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypercalcemia (with systemic absorption)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Betamethasone dipropionate is a Class III potent corticosteroid that suppresses inflammatory cytokines and immune cell infiltration in the skin. Calcipotriene is a vitamin D3 analog that promotes keratinocyte differentiation and reduces proliferation. Together, these agents provide complementary anti-inflammatory and anti-proliferative effects, delivered as a foam formulation for enhanced skin penetration and patient compliance.","oneSentence":"Enstilar combines a potent corticosteroid (betamethasone dipropionate) and a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:18.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis in adults"}]},"trialDetails":[{"nctId":"NCT03506477","phase":"PHASE4","title":"Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":"Plaque Psoriasis, Psoriasis","enrollment":25},{"nctId":"NCT03731091","phase":"PHASE3","title":"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2018-10-31","conditions":"Psoriasis Vulgaris","enrollment":494},{"nctId":"NCT03827876","phase":"PHASE4","title":"Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2019-01-16","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT03080545","phase":"PHASE4","title":"Enstilar in Combination With Biologic Agents","status":"COMPLETED","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2017-05-01","conditions":"Psoriasis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Enstilar 0.005%-0.064% Topical Foam","genericName":"Enstilar 0.005%-0.064% Topical Foam","companyName":"Psoriasis Treatment Center of Central New Jersey","companyId":"psoriasis-treatment-center-of-central-new-jersey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enstilar combines a potent corticosteroid (betamethasone dipropionate) and a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}